Selected research
Market Structure
Global Duvelisib for Relapsed CLL/SLL Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Duvelisib for Relapsed CLL/SLL market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Duvelisib for Relapsed CLL/SLL include Secura Bio and CSPC among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Duvelisib for Relapsed CLL/SLL market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Duvelisib for Relapsed CLL/SLL and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Duvelisib for Relapsed CLL/SLL sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Duvelisib for Relapsed CLL/SLL market size, projected growth trends, production technologies, key applications, and end-use industries.
Duvelisib for Relapsed CLL/SLL Segment by Company
Secura Bio
CSPC
Duvelisib for Relapsed CLL/SLL Segment by Type
25mg
15mg
Duvelisib for Relapsed CLL/SLL Segment by Application
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Duvelisib for Relapsed CLL/SLL Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duvelisib for Relapsed CLL/SLL market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Duvelisib for Relapsed CLL/SLL and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duvelisib for Relapsed CLL/SLL.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Duvelisib for Relapsed CLL/SLL market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duvelisib for Relapsed CLL/SLL manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Duvelisib for Relapsed CLL/SLL in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Duvelisib for Relapsed CLL/SLL in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 25mg
- 15mg
Applications
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Companies covered
- Secura Bio
- CSPC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Duvelisib for Relapsed CLL/SLL Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Duvelisib for Relapsed CLL/SLL Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Duvelisib for Relapsed CLL/SLL Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Duvelisib for Relapsed CLL/SLL Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Duvelisib for Relapsed CLL/SLL Market Dynamics
- 2.1 Duvelisib for Relapsed CLL/SLL Industry Trends
- 2.2 Duvelisib for Relapsed CLL/SLL Industry Drivers
- 2.3 Duvelisib for Relapsed CLL/SLL Industry Opportunities and Challenges
- 2.4 Duvelisib for Relapsed CLL/SLL Industry Restraints
3 Duvelisib for Relapsed CLL/SLL Market by Manufacturers
- 3.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Manufacturers (2021-2026)
- 3.2 Global Duvelisib for Relapsed CLL/SLL Sales by Manufacturers (2021-2026)
- 3.3 Global Duvelisib for Relapsed CLL/SLL Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Duvelisib for Relapsed CLL/SLL Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Duvelisib for Relapsed CLL/SLL Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Duvelisib for Relapsed CLL/SLL Manufacturers, Product Type & Application
- 3.7 Global Duvelisib for Relapsed CLL/SLL Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Duvelisib for Relapsed CLL/SLL Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Duvelisib for Relapsed CLL/SLL Players Market Share by Revenue in 2025
- 3.8.3 2025 Duvelisib for Relapsed CLL/SLL Tier 1, Tier 2, and Tier 3
4 Duvelisib for Relapsed CLL/SLL Market by Type
- 4.1 Duvelisib for Relapsed CLL/SLL Type Introduction
- 4.1.1 25mg
- 4.1.2 15mg
- 4.2 Global Duvelisib for Relapsed CLL/SLL Sales by Type
- 4.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2021-2032)
- 4.2.3 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2021-2032)
- 4.3 Global Duvelisib for Relapsed CLL/SLL Revenue by Type
- 4.3.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2021-2032)
- 4.3.3 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2021-2032)
5 Duvelisib for Relapsed CLL/SLL Market by Application
- 5.1 Duvelisib for Relapsed CLL/SLL Application Introduction
- 5.1.1 Chronic Lymphocytic Leukemia (CLL)
- 5.1.2 Small Lymphocytic Lymphoma (SLL)
- 5.2 Global Duvelisib for Relapsed CLL/SLL Sales by Application
- 5.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2021-2032)
- 5.2.3 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2021-2032)
- 5.3 Global Duvelisib for Relapsed CLL/SLL Revenue by Application
- 5.3.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2021-2032)
- 5.3.3 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2021-2032)
6 Global Duvelisib for Relapsed CLL/SLL Sales by Region
- 6.1 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region (2021-2032)
- 6.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Region (2021-2026)
- 6.2.2 Global Duvelisib for Relapsed CLL/SLL Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Duvelisib for Relapsed CLL/SLL Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Duvelisib for Relapsed CLL/SLL Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Duvelisib for Relapsed CLL/SLL Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Duvelisib for Relapsed CLL/SLL Revenue by Region
- 7.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Region
- 7.1.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Region (2021-2026)
- 7.1.3 Global Duvelisib for Relapsed CLL/SLL Revenue by Region (2027-2032)
- 7.1.4 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Duvelisib for Relapsed CLL/SLL Revenue (2021-2032)
- 7.2.2 North America Duvelisib for Relapsed CLL/SLL Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Duvelisib for Relapsed CLL/SLL Revenue (2021-2032)
- 7.3.2 Europe Duvelisib for Relapsed CLL/SLL Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Duvelisib for Relapsed CLL/SLL Revenue (2021-2032)
- 7.4.2 Asia-Pacific Duvelisib for Relapsed CLL/SLL Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Secura Bio
- 8.1.1 Secura Bio Company Information
- 8.1.2 Secura Bio Business Overview
- 8.1.3 Secura Bio Duvelisib for Relapsed CLL/SLL Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Secura Bio Duvelisib for Relapsed CLL/SLL Product Portfolio
- 8.1.5 Secura Bio Recent Developments
- 8.2 CSPC
- 8.2.1 CSPC Company Information
- 8.2.2 CSPC Business Overview
- 8.2.3 CSPC Duvelisib for Relapsed CLL/SLL Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 CSPC Duvelisib for Relapsed CLL/SLL Product Portfolio
- 8.2.5 CSPC Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Duvelisib for Relapsed CLL/SLL Value Chain Analysis
- 9.1.1 Duvelisib for Relapsed CLL/SLL Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Duvelisib for Relapsed CLL/SLL Production Mode & Process
- 9.2 Duvelisib for Relapsed CLL/SLL Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Duvelisib for Relapsed CLL/SLL Distributors
- 9.2.3 Duvelisib for Relapsed CLL/SLL Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst